3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Astec Lifesciences's 3-Year ROIIC % for the quarter that ended in Mar. 2026 was -89.76%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Astec Lifesciences's 3-Year ROIIC % or its related term are showing as below:
NSE:ASTEC's 3-Year ROIIC % is ranked worse than 88.84% of 251
companies
in the Agriculture industry
Industry Median: -2.28
vs NSE:ASTEC: -89.76
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Astec Lifesciences 3-Year ROIIC % Related Terms
Astec Lifesciences 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Astec Lifesciences's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ASTEC vs CTVA, CF, MOS: 3-Year ROIIC % Comparison
For the Agricultural Inputs subindustry, Astec Lifesciences's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Astec Lifesciences 3-Year ROIIC % vs Agriculture Industry
For the Agriculture industry and Basic Materials sector, Astec Lifesciences's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Astec Lifesciences's 3-Year ROIIC % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Astec Lifesciences (NSE:ASTEC) has a 3-Year ROIIC % of -89.76 as of Mar. 2026. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Astec Lifesciences and its competitors. According to the industry distribution chart, Astec Lifesciences ranks #223 out of 251 companies in the Agriculture industry, placing it in the top 88.8%.
Is Astec Lifesciences' 3-Year ROIIC % too high?
Astec Lifesciences' current 3-Year ROIIC % is -89.76. Based on the distribution chart, Astec Lifesciences ranks #223 out of 251 companies in the Agriculture industry, which is in the bottom quartile relative to peers. Overall, Astec Lifesciences has a GF Score™ of 79/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Astec Lifesciences' 3-Year ROIIC % compare to CTVA and CF?
According to the Agriculture industry distribution chart, Astec Lifesciences ranks #223 out of 251 companies for 3-Year ROIIC %. This places Astec Lifesciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for an Agriculture company?
A good 3-Year ROIIC % depends on the Agriculture industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Astec Lifesciences and its competitors. Astec Lifesciences's current 3-Year ROIIC % is -89.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astec Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Astec Lifesciences (NSE:ASTEC) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹991.55, compared to a current price of ₹689.20 — trading 30.5% below its estimated fair value. The current 3-Year ROIIC % is -89.76. Astec Lifesciences' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Astec Lifesciences (NSE:ASTEC), the current 3-Year ROIIC % is -89.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Astec Lifesciences (NSE:ASTEC) Overvalued in 2026?
Based on GuruFocus' analysis, Astec Lifesciences stock appears to be undervalued.
The current stock price of ₹689.20 is trading 30.5% below its estimated GF Value™ of ₹991.55.
GuruFocus considers Astec Lifesciences to be Significantly Undervalued.
Key valuation signals for NSE:ASTEC:
3-Year ROIIC %: -89.76
GF Value™: ₹991.55 vs. price of ₹689.20 (30.5% below fair value)
No single metric tells the full story. See the NSE:ASTEC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Astec Lifesciences Ltd manufactures & distributes a wide range of Agrochemical active ingredients and pharmaceutical intermediates. The company's products include agrochemicals, such as Triazole Fungicides, Herbicides, and Insecticides. The company is also into Intermediates & Specialty chemicals. Geographically, all the operations of the firm function through India; however, its products are sold in the Indian and overseas markets. It operates in the business segment of Agrochemicals and has a business presence in India and outside India.
79GF Score
Get the complete analysis for NSE:ASTEC
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ASTEC has been successfully added to your 
